 <h1>Omnicef Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>cefdinir</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about cefdinir. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Omnicef.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to cefdinir: oral capsule, oral powder for suspension</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, cefdinir (the active ingredient contained in Omnicef) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking cefdinir:</p><p>
<i>More common</i>
</p><ul>
<li>Diarrhea</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Black, tarry stools</li>
<li>chest pain</li>
<li>chills</li>
<li>cough</li>
<li>fever</li>
<li>painful or difficult urination</li>
<li>shortness of breath</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>swollen glands</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Abdominal or stomach cramps or tenderness</li>
<li>back, leg, or stomach pains</li>
<li>bleeding gums</li>
<li>blistering, peeling, or loosening of the skin</li>
<li>bloating</li>
<li>blood in the urine or stools</li>
<li>bloody nose</li>
<li>bloody or cloudy urine</li>
<li>bloody, black, or tarry stools</li>
<li>blue lips, fingernails, or skin</li>
<li>bruising</li>
<li>chest pain or discomfort</li>
<li>clay-colored stools</li>
<li>cold, clammy skin</li>
<li>confusion</li>
<li>coughing or vomiting blood</li>
<li>cracks in the skin</li>
<li>dark-colored urine</li>
<li>diarrhea, watery and severe, which may also be bloody</li>
<li>difficult or troubled breathing</li>
<li>difficulty with breathing or swallowing</li>
<li>dilated neck veins</li>
<li>dizziness</li>
<li>extreme fatigue</li>
<li>fast heartbeat</li>
<li>fast, weak pulse</li>
<li>feeling of discomfort</li>
<li>general body swelling</li>
<li>general tiredness and weakness</li>
<li>headache</li>
<li>heavier menstrual periods</li>
<li>high fever</li>
<li>hives</li>
<li>hoarseness</li>
<li>increased thirst</li>
<li>inflammation of the joints</li>
<li>irregular breathing</li>
<li>irregular heartbeat</li>
<li>irregular, fast or slow, or shallow breathing</li>
<li>itching</li>
<li>joint or muscle pain</li>
<li>light-colored stools</li>
<li>lightheadedness</li>
<li>loss of appetite</li>
<li>loss of consciousness</li>
<li>loss of heat from the body</li>
<li>muscle aches</li>
<li>muscle cramps or spasms</li>
<li>muscle pain or stiffness</li>
<li>nausea or vomiting</li>
<li>noisy breathing</li>
<li>nosebleeds</li>
<li>pain in the ankles or knees</li>
<li>pain or discomfort in the arms, jaw, back, or neck</li>
<li>painful, red lumps under the skin, mostly on the legs</li>
<li>pale skin</li>
<li>persistent bleeding or oozing from puncture sites, mouth, or nose</li>
<li>pinpoint red spots on the skin</li>
<li>problems with bleeding or clotting</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>rash</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>red, swollen skin</li>
<li>scaly skin</li>
<li>seizures</li>
<li>severe stomach pain</li>
<li>slow or irregular breathing</li>
<li>sudden decrease in the amount of urine</li>
<li>sweating</li>
<li>swelling of the face, fingers, feet, or lower legs</li>
<li>swollen lymph glands</li>
<li>tightness in the chest</li>
<li>unpleasant breath odor</li>
<li>unusual weight loss</li>
<li>upper right abdominal or stomach pain</li>
<li>vomiting of blood</li>
<li>weight gain</li>
<li>wheezing</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of cefdinir may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Itching of the vagina or genital area</li>
<li>pain during sexual intercourse</li>
<li>thick, white vaginal discharge with no odor or with a mild odor</li>
<li>vaginal yeast infection</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Acid or sour stomach</li>
<li>belching</li>
<li>constipation</li>
<li>dry mouth</li>
<li>excess air or gas in the stomach or intestines</li>
<li>full feeling</li>
<li>heartburn</li>
<li>increase in body movements</li>
<li>increased clear or white vaginal discharge</li>
<li>indigestion</li>
<li>lack or loss of strength</li>
<li>passing gas</li>
<li>rash with flat lesions or small raised lesions on the skin</li>
<li>sleepiness or unusual drowsiness</li>
<li>soreness or redness around the fingernails and toenails</li>
<li>stomach discomfort, upset, or pain</li>
<li>unable to sleep</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Burning, dry, or itching eyes</li>
<li>discharge, excessive tearing</li>
<li>redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid</li>
<li>swelling or inflammation of the mouth</li>
</ul><p>
<!-- end oral capsule, oral powder for suspension --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to cefdinir: oral capsule, oral powder for reconstitution</i></p><h3>Gastrointestinal</h3><p>Reddish-colored stools have occurred when cefdinir (the active ingredient contained in Omnicef) was taken with iron-containing products, and may be due to the formation of non-absorbable complexes in the GI tract.<sup>[Ref]</sup></p><p>Gastrointestinal side effects have included diarrhea (15%), nausea (3%), abdominal pain (1%), dyspepsia (0.7%), flatulence (0.7%), vomiting (0.7%), anorexia (0.3%), constipation (0.3%), dry mouth (03%), abnormal stools (0.3%), moniliasis (0.2%) and pseudomembranous colitis.  Adverse effects reported during postmarketing experience with cefdinir, regardless of causality, have included stomatitis, acute enterocolitis, bloody diarrhea, hemorrhagic colitis, melena, upper GI bleed, peptic ulcer, and ileus.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Hypersensitivity reactions associated with cephalosporin class antibiotics have included allergic reactions, anaphylaxis, Stevens-Johnson syndrome, erythema multiforme, and toxic epidermal necrolysis.  Adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef)  regardless of causality, have included anaphylaxis (with rare cases of fatality), serum sickness-like reactions, Stevens-Johnson syndrome, and toxic epidermal necrolysis.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Dermatologic side effects have included rash (0.9%) and pruritus (0.2%).  Adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef)  regardless of causality, have included exfoliative dermatitis, erythema multiforme, and erythema nodosum.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Genitourinary side effects have included vaginal moniliasis (4% of women), vaginitis (1% of women), leukorrhea (0.2% of women), increased urine leukocytes (2%), increased urine protein (1%), increased microhematuria (1%), increased urine glucose (0.9%), increased urine specific gravity (0.6%), decreased urine specific gravity (0.2%), increased urine pH (0.2%).  Cephalosporins as a class have been associated with false-positive tests for urine glucose.<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Nervous system side effects have included headache (2%), dizziness (0.3%), insomnia (0.2%), asthenia (0.2%), and somnolence (0.2%).  Some cephalosporins have been associated with seizures in renally impaired patients.  Adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef)  regardless of causality, have included loss of consciousness.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Hematologic side effects have included increased lymphocytes (1%), decreased lymphocytes (0.2%), increased white blood cells (0.9%), decreased white blood cells (0.7%), increased eosinophils (0.7%), decreased hemoglobin (0.3%), increased polymorphonuclear neutrophils (0.3%), decreased polymorphonuclear neutrophils (0.2%), and increased platelets (0.2%).  Adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef)  regardless of causality, have included granulocytopenia, pancytopenia, leukopenia, thrombocytopenia, idiopathic thrombocytopenic purpura, hemolytic anemia, bleeding tendency, coagulation disorder, and disseminated intravascular coagulation.  Cephalosporins as a class have been associated with aplastic anemia, hemolytic anemia, prolonged prothrombin time, hemorrhage, neutropenia, pancytopenia, and agranulocytosis.<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Metabolic side effects have included increased gamma-glutamyltransferase (1%), increased alanine aminotransferase (0.7%), decreased bicarbonate (0.6%), increased phosphorus (0.6%), decreased phosphorus (0.3%), increased aspartate aminotransferase (0.4%), increased alkaline phosphatase (0.3%), increased blood urea nitrogen (0.3%), increased bilirubin (0.2%), increased lactate dehydrogenase (0.2%), and increased potassium (0.2%).<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Hepatic side effects associated with cephalosporins as a class have included hepatic dysfunction, including cholestasis.  Adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef)  regardless of causality, have included acute hepatitis, cholestasis, fulminant hepatitis, hepatic failure, jaundice, and increased amylase.<sup>[Ref]</sup></p><h3>Renal</h3><p>Renal side effects associated with cephalosporins as a class have included renal dysfunction and toxic nephropathy.  Adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef)  regardless of causality, have included acute renal failure and nephropathy.<sup>[Ref]</sup></p><h3>Ocular</h3><p>Ocular adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef)  regardless of causality, have included conjunctivitis.<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Respiratory adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef)  regardless of causality, have included acute respiratory failure, asthmatic attack, drug-induced pneumonia, eosinophilic pneumonia, and idiopathic interstitial pneumonia.<sup>[Ref]</sup></p><h3>Other</h3><p>Adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef)  regardless of causality, have included fever, shock, feeling of suffocation, and facial and laryngeal edema.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Cardiovascular adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef)  regardless of causality, have included cardiac failure, chest pain, myocardial infarction, hypertension, and allergic vasculitis.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Musculoskeletal adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef)  regardless of causality, have included involuntary movements and rhabdomyolysis.<sup>[Ref]</sup></p><h3>Other</h3><p>Geriatric patients have been reported to experience a lower rate of adverse events, including diarrhea, than younger patients.<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Tack KJ, Henry DC, Gooch WM, Brink DN, Keyserling C "Five-day cefdinir treatment for streptococcal pharyngitis." Antimicrob Agents Chemother 42 (1998): 1073-5</p><p id="ref_2">2. Tack KJ, Keyserling CH, McCarty J, Hedrick JA "Study of use of cefdinir versus cephalexin for treatment of skin infections in pediatric patients. The Cefdinir Pediatric Ski Infection Study Group." Antimicrob Agents Chemother 41 (1997): 739-42</p><p id="ref_3">3. Tack KJ, Hedrick JA, Rothstein E, Nemeth MA, Keyserling C, Pichichero ME "A study of 5-day cefdinir treatment for streptococcal pharyngitis in children. Cefdinir Pediatric Pharyngitis Study Group." Arch Pediatr Adolesc Med 151 (1997): 45-9</p><p id="ref_4">4. Tack KJ, Littlejohn TW, Mailloux G, Wolf MM, Keyserling CH "Cefdinir versus cephalexin for the treatment of skin and skin-structure infections." Clin Ther 20 (1998): 244-56</p><p id="ref_5">5. Kato S, Ebina K, Ozawa A, Naganuma H, Nakagawa H "Antibiotic-associated hemorrhagic colitis without Clostridium difficile toxin in children." J Pediatr 126 (1995): 1008-10</p><p id="ref_6">6. "Product Information. Omnicef (cefdinir)." Parke-Davis, Morris Plains, NJ. </p><p id="ref_7">7. Romano A, Mayorga C, Torres MJ, Artesani MC, Suau R, Sanchez F, Perez E, Venuti A, Blanca M "Immediate allergic reactions to cephalosporins: Cross-reactivity and selective responses." J Allerg Clin Immunol 106 (2000): 1177-83</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>Cefdinir - Can a capsule be broken open and sprinkled on food?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Omnicef (cefdinir)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>47 Reviews</li>
<li>Generic Availability</li>
<li>Drug class: third generation cephalosporins</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Omnicef &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Omnicef Omni-Pac</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Sinusitis</li>
<li>Otitis Media</li>
<li>Bronchitis</li>
<li>Pneumonia</li>
<li data-more-config-id="list-data-resources-conditions">... +4 more</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to cefdinir: oral capsule, oral powder for reconstitution</i></p><h3>Gastrointestinal</h3><p>Reddish-colored stools have occurred when cefdinir (the active ingredient contained in Omnicef) was taken with iron-containing products, and may be due to the formation of non-absorbable complexes in the GI tract.<sup>[Ref]</sup></p><p>Gastrointestinal side effects have included diarrhea (15%), nausea (3%), abdominal pain (1%), dyspepsia (0.7%), flatulence (0.7%), vomiting (0.7%), anorexia (0.3%), constipation (0.3%), dry mouth (03%), abnormal stools (0.3%), moniliasis (0.2%) and pseudomembranous colitis.  Adverse effects reported during postmarketing experience with cefdinir, regardless of causality, have included stomatitis, acute enterocolitis, bloody diarrhea, hemorrhagic colitis, melena, upper GI bleed, peptic ulcer, and ileus.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Hypersensitivity reactions associated with cephalosporin class antibiotics have included allergic reactions, anaphylaxis, Stevens-Johnson syndrome, erythema multiforme, and toxic epidermal necrolysis.  Adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef)  regardless of causality, have included anaphylaxis (with rare cases of fatality), serum sickness-like reactions, Stevens-Johnson syndrome, and toxic epidermal necrolysis.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Dermatologic side effects have included rash (0.9%) and pruritus (0.2%).  Adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef)  regardless of causality, have included exfoliative dermatitis, erythema multiforme, and erythema nodosum.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Genitourinary side effects have included vaginal moniliasis (4% of women), vaginitis (1% of women), leukorrhea (0.2% of women), increased urine leukocytes (2%), increased urine protein (1%), increased microhematuria (1%), increased urine glucose (0.9%), increased urine specific gravity (0.6%), decreased urine specific gravity (0.2%), increased urine pH (0.2%).  Cephalosporins as a class have been associated with false-positive tests for urine glucose.<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Nervous system side effects have included headache (2%), dizziness (0.3%), insomnia (0.2%), asthenia (0.2%), and somnolence (0.2%).  Some cephalosporins have been associated with seizures in renally impaired patients.  Adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef)  regardless of causality, have included loss of consciousness.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Hematologic side effects have included increased lymphocytes (1%), decreased lymphocytes (0.2%), increased white blood cells (0.9%), decreased white blood cells (0.7%), increased eosinophils (0.7%), decreased hemoglobin (0.3%), increased polymorphonuclear neutrophils (0.3%), decreased polymorphonuclear neutrophils (0.2%), and increased platelets (0.2%).  Adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef)  regardless of causality, have included granulocytopenia, pancytopenia, leukopenia, thrombocytopenia, idiopathic thrombocytopenic purpura, hemolytic anemia, bleeding tendency, coagulation disorder, and disseminated intravascular coagulation.  Cephalosporins as a class have been associated with aplastic anemia, hemolytic anemia, prolonged prothrombin time, hemorrhage, neutropenia, pancytopenia, and agranulocytosis.<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Metabolic side effects have included increased gamma-glutamyltransferase (1%), increased alanine aminotransferase (0.7%), decreased bicarbonate (0.6%), increased phosphorus (0.6%), decreased phosphorus (0.3%), increased aspartate aminotransferase (0.4%), increased alkaline phosphatase (0.3%), increased blood urea nitrogen (0.3%), increased bilirubin (0.2%), increased lactate dehydrogenase (0.2%), and increased potassium (0.2%).<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Hepatic side effects associated with cephalosporins as a class have included hepatic dysfunction, including cholestasis.  Adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef)  regardless of causality, have included acute hepatitis, cholestasis, fulminant hepatitis, hepatic failure, jaundice, and increased amylase.<sup>[Ref]</sup></p><h3>Renal</h3><p>Renal side effects associated with cephalosporins as a class have included renal dysfunction and toxic nephropathy.  Adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef)  regardless of causality, have included acute renal failure and nephropathy.<sup>[Ref]</sup></p><h3>Ocular</h3><p>Ocular adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef)  regardless of causality, have included conjunctivitis.<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Respiratory adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef)  regardless of causality, have included acute respiratory failure, asthmatic attack, drug-induced pneumonia, eosinophilic pneumonia, and idiopathic interstitial pneumonia.<sup>[Ref]</sup></p><h3>Other</h3><p>Adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef)  regardless of causality, have included fever, shock, feeling of suffocation, and facial and laryngeal edema.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Cardiovascular adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef)  regardless of causality, have included cardiac failure, chest pain, myocardial infarction, hypertension, and allergic vasculitis.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Musculoskeletal adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef)  regardless of causality, have included involuntary movements and rhabdomyolysis.<sup>[Ref]</sup></p><h3>Other</h3><p>Geriatric patients have been reported to experience a lower rate of adverse events, including diarrhea, than younger patients.<sup>[Ref]</sup></p><p id="ref_1">1. Tack KJ, Henry DC, Gooch WM, Brink DN, Keyserling C "Five-day cefdinir treatment for streptococcal pharyngitis." Antimicrob Agents Chemother 42 (1998): 1073-5</p><p id="ref_2">2. Tack KJ, Keyserling CH, McCarty J, Hedrick JA "Study of use of cefdinir versus cephalexin for treatment of skin infections in pediatric patients. The Cefdinir Pediatric Ski Infection Study Group." Antimicrob Agents Chemother 41 (1997): 739-42</p><p id="ref_3">3. Tack KJ, Hedrick JA, Rothstein E, Nemeth MA, Keyserling C, Pichichero ME "A study of 5-day cefdinir treatment for streptococcal pharyngitis in children. Cefdinir Pediatric Pharyngitis Study Group." Arch Pediatr Adolesc Med 151 (1997): 45-9</p><p id="ref_4">4. Tack KJ, Littlejohn TW, Mailloux G, Wolf MM, Keyserling CH "Cefdinir versus cephalexin for the treatment of skin and skin-structure infections." Clin Ther 20 (1998): 244-56</p><p id="ref_5">5. Kato S, Ebina K, Ozawa A, Naganuma H, Nakagawa H "Antibiotic-associated hemorrhagic colitis without Clostridium difficile toxin in children." J Pediatr 126 (1995): 1008-10</p><p id="ref_6">6. "Product Information. Omnicef (cefdinir)." Parke-Davis, Morris Plains, NJ. </p><p id="ref_7">7. Romano A, Mayorga C, Torres MJ, Artesani MC, Suau R, Sanchez F, Perez E, Venuti A, Blanca M "Immediate allergic reactions to cephalosporins: Cross-reactivity and selective responses." J Allerg Clin Immunol 106 (2000): 1177-83</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>Cefdinir - Can a capsule be broken open and sprinkled on food?</li>
</ul><h2>More about Omnicef (cefdinir)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>47 Reviews</li>
<li>Generic Availability</li>
<li>Drug class: third generation cephalosporins</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Omnicef &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Sinusitis</li>
<li>Otitis Media</li>
<li>Bronchitis</li>
<li>Pneumonia</li>
<li data-more-config-id="list-data-resources-conditions">... +4 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>